Contrasting iSpecimen (NASDAQ:ISPC) & GeneDx (NASDAQ:WGS)

GeneDx (NASDAQ:WGS) and iSpecimen (NASDAQ:ISPC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for GeneDx and iSpecimen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1	3	7	0	2.55
iSpecimen	1	0	0	0	1.00

GeneDx presently has a consensus price target of $129.22, indicating a potential downside of 7.52%. Given GeneDx’s stronger consensus rating and higher possible upside, analysts clearly believe GeneDx is more favorable than iSpecimen.

Risk and Volatility

GeneDx has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500.

Insider and Institutional Ownership

61.7% of GeneDx shares are held by institutional investors. Comparatively, 13.6% of iSpecimen shares are held by institutional investors. 29.6% of GeneDx shares are held by insiders. Comparatively, 12.2% of iSpecimen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares GeneDx and iSpecimen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneDx	0.52%	20.22%	11.89%
iSpecimen	-172.48%	-395.15%	-121.72%

Valuation and Earnings

This table compares GeneDx and iSpecimen”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$402.19 million	9.98	-$52.29 million	$0.09	1,552.56
iSpecimen	$5.91 million	1.05	-$12.50 million	($9.51)	-0.07

iSpecimen has lower revenue, but higher earnings than GeneDx. iSpecimen is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Summary

GeneDx beats iSpecimen on 13 of the 14 factors compared between the two stocks.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

About iSpecimen

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.